Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care

Lilly highlighted multiple positive Phase 3 and subgroup data updates for Foundayo (orforglipron), Mounjaro, and retatrutide ahead of the ADA Scientific Sessions. Foundayo showed up to 1.7% A1C reduction vs. 0.8% for dapagliflozin, superior results versus oral semaglutide, and up to 2.1% A1C reduction vs. 0.8% with placebo; retatrutide delivered up to 70.3 lbs (28.3%) weight loss at 80 weeks and up to 2.0% A1C reduction at 40 weeks. The readout supports Lilly’s diabetes/obesity pipeline, but the article is primarily a conference preview and press release rather than a near-term financial catalyst.

Analysis

LLY is widening the moat in incretin therapy by attacking the market from three angles: oral convenience, injectable efficacy, and lifecycle breadth. The strategic point is not just “more data”; it is that Lilly is trying to force prescribers into a platform choice where the company can keep patients inside its own ecosystem as they move from obesity to diabetes to cardiometabolic complications. That should increase switching costs and reduce the odds that payers can segment the market cleanly by indication.

The more interesting second-order effect is on the competitive set. An oral GLP-1 with no food/water constraints lowers the barrier to initiation and may pull share from lower-intensity oral agents first, but the bigger threat is to companies relying on pill convenience as their only edge. If the oral asset is perceived as good-enough efficacy with materially better adherence, it can compress the value of “tablets are easier” positioning and push competitors toward either price concessions or combination strategies. On the injectable side, retatrutide’s emerging profile raises the bar for next-gen obesity drugs: even if it remains investigational, it can reset the market’s expectations for magnitude of weight loss and make currently marketed agents look like maintenance therapies rather than best-in-class solutions.

Near term, the main risk is not efficacy but tolerability, discontinuation, and payer scrutiny. With obesity/diabetes drugs, small deltas in GI dropout rates and adherence can overwhelm headline efficacy over 6-12 months, especially if real-world persistence is weaker than trial performance. Another risk is that broad label expansion and differentiated mechanisms invite tougher utilization management from PBMs, which could slow net pricing even if gross demand remains strong.

Key Decisions for Investors

• Stay long LLY into the next 1-3 months of data cadence; use pullbacks to add, because the setup supports multiple re-rating if prescriber preference shifts toward a single-platform story. Risk/reward remains favorable unless discontinuation or payer commentary materially worsens.
• Short a basket of oral/obesity challengers on relative weakness versus LLY over 4-8 weeks; the cleaner expression is a long LLY / short competitor pair to isolate share-shift rather than sector beta.
• Buy medium-dated call spreads on LLY rather than outright calls to capture event-driven upside while limiting premium decay if the market has already partially priced the pipeline narrative.
• Watch for any read-through to payer controls; if utilization management tightens, rotate part of the long into a defensive pair trade against retail/pharmacy intermediaries most exposed to rebating pressure.
• If retatrutide continues to outperform expectations in follow-on data, consider a longer-dated short on names whose valuation depends on being the obesity efficacy leader; the risk/reward improves over 6-12 months as the market starts to discount future share loss.